×

INSYS Therapeutics to Report Third Quarter 2017 Results on Nov. 2

PHOENIX, Oct. 19, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today announced that it will release its third quarter 2017 financial results on Thursday, Nov. 2, before the U.S. financial markets open.

Following the release of the financial results, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conference call at 8:30 a.m. Eastern Daylight Time.

Investors, analysts and members of the media interested in listening to the live presentation are encouraged to join a webcast of the call available on the company’s website at https://www.insysrx.com/. Interested parties may also participate in the call by dialing (844) 263-8304 (from inside the U.S.) or (213) 358-0958 (from outside the U.S.). A webcasted replay of the conference call will be available a few hours after the event through the INVESTORS section, under the NEWS & EVENTS tab for “Presentations.”

About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets SUBSYS® (fentanyl sublingual spray), CII, and SYNDROS® (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.

SUBSYS® and SYNDROS® are trademarks of INSYS Development Company, Inc., a subsidiary of INSYS Therapeutics, Inc.

NOTE: All trademarks and registered trademarks are the property of their respective owners.

CONTACT:

Media Relations
Joe McGrath
Senior Director, Corporate Communications
INSYS Therapeutics
480-500-3101
jmcgrath@insysrx.com

Investor Relations
Jackie Marcus or Chris Hodges
Alpha IR Group
312-445-2870
INSY@alpha-ir.com

Source:Insys Therapeutics, Inc.